Inhibition of IRE1α-mediated XBP1 mRNA cleavage by XBP1 reveals a novel regulatory process during the unfolded protein response [version 2; peer review: 2 approved]

Fiona Chalmers¹, Marcel van Lith¹, Bernadette Sweeney², Katharine Cain², Neil J. Bulleid²¹

¹Institute of Molecular, Cellular and Systems Biology, University of Glasgow, Glasgow, G12 8QQ, UK
²UCB Pharma Slough, Slough, SL1 3WE, UK

Abstract

Background: The mammalian endoplasmic reticulum (ER) continuously adapts to the cellular secretory load by the activation of an unfolded protein response (UPR). This stress response results in expansion of the ER, upregulation of proteins involved in protein folding and degradation, and attenuation of protein synthesis. The response is orchestrated by three signalling pathways each activated by a specific signal transducer, either inositol requiring enzyme α (IRE1α), double-stranded RNA-activated protein kinase-like ER kinase (PERK) or activating transcription factor 6 (ATF6). Activation of IRE1α results in its oligomerisation, autophosphorylation and stimulation of its ribonuclease activity. The ribonuclease initiates the splicing of an intron from mRNA encoding the transcription factor, X-box binding protein 1 (XBP1), as well as degradation of specific mRNAs and microRNAs.

Methods: To investigate the consequence of expression of exogenous XBP1, we generated a stable cell-line expressing spliced XBP1 mRNA under the control of an inducible promotor.

Results: Following induction of expression, high levels of XBP1 protein were detected, which allowed upregulation of target genes in the absence of induction of the UPR. Remarkably under stress conditions, the expression of exogenous XBP1 repressed splicing of endogenous XBP1 mRNA without repressing the activation of PERK.

Conclusions: These results illustrate that a feedback mechanism exists to attenuate Ire1α ribonuclease activity in the presence of XBP1.

Keywords

Unfolded protein response, IRE1α, XBP1, ER stress response.
Introduction

The endoplasmic reticulum (ER) is the site of protein folding and post-translational modification of secreted and transmembrane proteins. Under stress conditions such as glucose starvation or a viral infection, the folding capacity of the ER can become compromised, leading to a potentially lethal build-up of unfolded or misfolded proteins. Protein folding homeostasis can be restored by triggering of a stress response called the unfolded protein response (UPR). This complex and tightly-regulated process has downstream effects that enable the ER to adapt to stress conditions, and if this pro-survival strategy does not successfully restore ER homeostasis then pro-apoptotic signalling is induced.

The mammalian UPR is formed from three distinct but overlapping signalling branches, each governed by an initial effector protein localised to the ER membrane. These proteins are activating transcription factor 6 (ATF6), protein kinase-like ER kinase (PERK) and inositol requiring enzyme α (IRE1α), and are activated in the presence of a build-up of incorrectly folded proteins. Of these three mammalian UPR effectors, IRE1α is the most conserved with its yeast homolog being solely responsible for the UPR in lower eukaryotes. The activation of its cytosolic endoribonuclease (RNase) domain enables processing of unspliced X-box binding protein 1 (XBPI) mRNA (XBPIu). Spliced transcripts (XBPIs) are translated into the protein XBPI, a transcription factor that upregulates the expression of proteins involved in ER protein folding, ER associated degradation (ERAD) and lipid biogenesis as part of a concerted effort to increase the capacity of the ER to cope with unfolded proteins.

In addition to its RNase domain, IRE1α also contains a cytosolic kinase domain and a luminal domain that senses ER stress, and these domains are connected by a single transmembrane domain. Upon activation, IRE1α forms dimers, via ‘face-to-face’ interactions. The ‘face-to-face’ dimer displays no RNase activity and represents an early stage in IRE1α activation; its main purpose is to bring the kinase domains into proximity to enable transautophosphorylation. Phosphorylation induces a change in structure into a ‘back-to-back’ dimer, which brings the RNase domains into direct contact, forming a functional RNase active site capable of splicing XBPIu.

Activated IRE1α is also able to digest miRNAs and miRNAs during a process termed Regulated IRE1α Dependent Decay (RIDD). It has been suggested that the specificity of IRE1α changes during the UPR, initially cleaving XBPIu, but during prolonged stress switching to the cleavage of mRNA coding for proteins upregulated during the UPR. The consequence is an exacerbation of the stress leading to apoptosis. In addition, the cleavage of miRNAs responsible for the downregulation of caspase-2 results in elevated levels of this protease and induction of apoptosis through the BAX/BAK-dependent pathway. What regulates this switch in specificity is unknown, but could be related to subtle changes in IRE1α phosphorylation status, conformation or interaction with IRE1α regulators.

Given the potential for IRE1α to activate proapoptotic factors during prolonged ER stress, it is important to understand how IRE1α activity is attenuated. Previous studies indicate that this attenuation may be the result of multiple mechanisms to reduce IRE1α protein, reverse oligomerisation or alter phosphorylation status. For example, IRE1α transcripts can be degraded by RIDD and activated IRE1α dimers can be dephosphorylated by the phosphatase PP2Ce. In addition, the oxidation of thiols within the IRE1α luminal domain occurs during activation, a modification that is reversed during IRE1α attenuation. This mechanism of attenuation is dependent upon oxidoreductase activity provided by P5, a member of the protein disulfide isomerase family. Finally, the depletion of XBPI can be facilitated by XBPI, the protein translated from XBPIu transcripts, and involves the binding of XBPI to XBPI and subsequent trafficking to the 26S proteasome for degradation.

In order to explore the regulatory mechanisms of IRE1α, we investigated the impact of high levels of expression of XBPI on the activity of IRE1α. Our results show that an abundance of XBPI represses endogenous XBPI splicing during unstressed and stress conditions. This repression may represent a regulatory mechanism, where persistent ER stress attenuates IRE1α RNase activity at least towards XBPI mRNA.

Materials and methods

Generation of stable cell lines

CHO-S X was generated by transfecting 4 μg of pTetOne vector (Clontech), containing cDNA for the human XBPIs sequence, into CHO-S cells (Life Technologies), co-transfected with 200ng of a linear selectable marker for puromycin (a vector:marker ratio of 20:1), with 4.2 μl of the transfection reagent NovaCHOice (Novagen). Transfected cells and untransfected control cells were grown in a 6 cm diameter dish in adherent culture, and after 24 h of growth were trypsinised and 1/10 of the cells were transferred to a 15 cm dish and grown in 20 ml medium containing 12.5 μg/ml puromycin. The transfected cells were grown for approximately 10 days, refreshing the selection medium every 3–4 days. Colonies were identified and removed from the dish using trypsin-soaked cloning discs and transferred into the wells of a 12 well plate, with one colony per well. The clones were grown under selection for another 3–5 days until the well was confluent, then the surviving clones were transferred into T25 flasks and later T75 flasks. To generate the CHO-S XB cell line, CHO-S X cells were transfected with a BFP construct using the same method as described above. The construct contained a G418 resistance gene, so the linear selectable marker was not required. Transfected cells were maintained under the dual selection of both 12.5 μg/mL puromycin and 2 mg/mL G418.
Crude lysates were mixed with 0.2 M Tris-HCl (pH 6.8) containing 10% (w/v) SDS, 20% (v/v) glycerol and 0.05% (w/v) bromophenol blue (sample buffer) in a 4:1 ratio of lysate to sample buffer. Dithiothreitol (DTT) was added as a reducing agent at a working concentration of 20 mM. Polyacrylamide gels were loaded with 20–30 μl of this sample mixture and run at 20 mA per gel.

Western blot
After separation, the samples were transferred to a nitrocellulose membrane (GE Healthcare) by wet transfer for 1 h at 250 mA using 25 mM Tris-HCl containing 200 mM glycine, 3.5 mM SDS and 20% (v/v) methanol. The blots were blocked in 5% (w/v) non-fat milk powder (Marvel) in 50 mM Tris-HCl buffer (pH 7.5) containing 150 mM NaCl and 0.1% (v/v) Tween (TBST) for 1 h. Primary antibodies were diluted in TBST and incubated overnight. Washes were performed three times for 10 min in TBST. Secondary antibodies were diluted in TBST and incubated for 1 h, and the blots shielded from light throughout the incubation. Blots were developed using the Odyssey SA scanner (Licor). The following primary antibodies were used: rabbit polyclonal anti-PDI<sup>SP</sup>, 1:500; rabbit polyclonal anti-XBP1<sup>s</sup> (Biolegend, Cat# 619502, RRID:AB_315907), 1:500; rabbit monoclonal anti-PERK, (CellSignalling, Cat# 3192 RRID:AB_2095847), 1:1000; mouse monoclonal anti-GAPDH, (Ambion, Cat# AM4300, RRID:AB_437392), 1:10000; rabbit polyclonal anti-actin, (Sigma-Aldrich Cat# A2103, RRID:AB_476694), 1:500. The following secondary antibodies were used: donkey polyclonal anti-mouse 680RD, (LI-COR Biosciences Cat# 926-68072, RRID:AB_10953628) 1:10000; donkey polyclonal anti-mouse 800CW (LI-COR Biosciences Cat# 926-32212, RRID:AB_621847), 1:1000; donkey polyclonal anti-rabbit 680RD, (LI-COR Biosciences Cat# 926-68073, RRID:AB_10954442), 1:10000; donkey polyclonal anti-rabbit 800CW (LI-COR Biosciences Cat# 926-32213, RRID:AB_621848), 1:10000.

ER Tracker treatment
ER Tracker Green BODIPY FL Glibenclamide (Molecular Probes) was dissolved in DMSO to a 1 mM stock concentration. Treated cells were stained with 250 nM ER Tracker in Hank’s Balanced Salt Solution (HBSS) for 30 min, then trypsinised and resuspended in DMEM.

ER stress treatments
Dithiothreitol (DTT) (Melford Labs) was prepared as a 1 M stock in water and used at a 2.5 mM working concentration. Thapsigargin (Sigma-Aldrich) was prepared as a 2 mM stock in DMSO and used at 4 μM. Tunicamycin (Sigma-Aldrich) was prepared as a 10 mg/mL stock in DMSO and used at 10 μg/mL. PERK inhibitor (Tocris) was prepared as a 10 mM stock in DMSO and used at 2.5 μM. Treatments were added for 3 h to cells that had been pretreated with doxycycline for 48 h.

Flow cytometry
Cells were washed once in HBSS then run on a FACS Canto II flow cytometer (BD Biosciences) in HBSS. ER Tracker Green has an excitation at 504 nm and emission at 511 nm, which can be detected using the FITC filter on the flow cytometer. The data obtained was analysed using Flowing Software v2.5.1 (Turku Bioimaging).

Results
To investigate the consequence of overexpression of human XBP1s in CHO-S cells, we created a stable cell-line expressing XBP1s mRNA under the control of a doxycycline inducible promoter.
No XBP1S was detected unless doxycycline was included in the medium (Figure 1). Such tight regulation of expression allowed us to evaluate the effect of overexpression of XBP1s in the same cell line simply by culturing cells in the presence or absence of doxycycline. Interestingly additional bands at about 70 and 100 kDa can be observed which are specific to the induced sample. Similar species have been reported and are thought to represent XBP1S that has undergone SUMOylation. 

To study the activation of IRE1α RNase activity, we assessed the cleavage of XBP1u mRNA before and after induction of human XBP1s expression, using an RT-PCR assay. By designing primers that flank the XBP1 spliced intron, cDNA derived from XBP1s and XBP1u transcripts can be amplified by PCR and distinguished from each other by a subtle, 26bp difference in product size when run on an agarose gel. This assay is also known to generate a third PCR product, shown diagrammatically (Figure 2A), which is

![Figure 1](image1.png)

**Figure 1.** Induction of XBP1S expression in CHO-S XB cells. Western blot of lysates from CHO-S XB cells either uninduced or induced with doxycycline (Dox) for 3 days, probed with anti-XBP1s and anti-GAPDH as indicated. The blot is representative of the results obtained from three separate experiments.

![Figure 2](image2.png)

**Figure 2.** Consequence of XBP1s expression on XBP1u splicing in cell lines following endoplasmic reticulum stress. (A) Schematic of the three possible cDNA products generated by primers that flank the XBP1 spliced intron (indicated in grey). Single stranded cDNA can anneal to either its complementary strand to generate double stranded XBP1u and XBP1s products, or generate a hybrid, XBP1h, formed from one strand XBP1u and one strand XBP1s. Of these three PCR products, XBP1s migrates the furthest on an agarose gel, followed by XBP1h and then by XBP1u, leading to the appearance of three distinct DNA bands. Adapted from 21. (B–E) XBP1 splice assay of cDNA extracted from either (B,D) CHO-S or (C,E) CHO-S XB cells treated with doxycycline (Dox; for 3 days) and/or tunicamycin (Tn; for 3 h) as indicated. PCR reactions contained primers that anneal only to the endogenous CHO XBP1 sequence (B,C) or primers that anneal to both the endogenous sequence and the exogenous XBP1s transcripts (D,E). The experiment was performed at least three times, data from a representative experiment is shown.
thought to be a hybrid double-stranded cDNA product consisting of one strand XBP1s and one strand XBP1u. This hybrid product migrates above double-stranded XBP1u on an agarose gel due to its bulkier structure. Two sets of primers were designed for the assay: the first set was designed to only anneal to the endogenous hamster sequence of XBP1, and these primers were used to quantify only endogenous XBP1s and XBP1u. The second set was designed to bind to both forms of endogenous CHO XBP1, and also to the exogenous human XBP1s transcript, allowing visualisation of all forms of XBP1 present in the cell.

In the absence of cell-stress, the endogenous XBP1 mRNA in CHO-S cells was present as a mixture of unspliced and hybrid forms (Figures 2B and D). This result is consistent with a basal level of UPR signalling reported to be active under normal physiological conditions. As expected, there was no change in the splicing pattern following treatment with doxycycline, indicating that this chemical alone does not induce the UPR. Following treatment with the ER stress inducer tunicamycin, all of the XBP1 mRNA was converted to either the spliced or hybrid form indicative of a strong UPR (Figures 2B and D). The splicing pattern of endogenous XBP1 mRNA in CHO-S XB cells in the absence of doxycycline, with or without cell stress was similar to that in CHO-S cells (Figure 2C). However, in the absence of cell stress incubation with doxycycline to induce XBP1s expression prevented any splicing of endogenous XBP1 mRNA, as evidenced by the absence of the hybrid form. Doxycycline induced expression of exogenous XBP1s, as seen by the presence of XBP1s when primers recognising both the human and hamster XBP1 were used in the assay (Figure 2E). We consistently observed an increase in expression of XBP1u following induction of XBP1s expression, indicating the upregulation of XBP1u expression by XBP1s, as shown previously. Under conditions of ER stress XBP1 mRNA was efficiently spliced in the absence of doxycycline, but this splicing was dramatically repressed after doxycycline treatment (Figure 2C). This result indicates that XBP1 splicing by IRE1α is largely prevented in cells overexpressing XBP1s.

To determine whether there was a correlation between the induction of expression of exogenous XBP1s and the repression of IRE1α cleavage of endogenous XBP1 mRNA, we titrated the amount of added doxycycline to induce increasing amounts of exogenous XBP1s. The effect on cleavage of endogenous XBP1 mRNA became apparent after treating with 50 ng/ml of doxycycline both in the absence or presence of tunicamycin-induced ER stress (Figures 3A and B). The effect increased with increasing concentrations of doxycycline with the greatest repression being most apparent at 1000 ng/ml in the presence of tunicamycin. When the presence of exogenously expressed XBP1s was evaluated using primers that amplify endogenous and exogenous XBP1, a clear increase in the XBP1s signal was observed at 50 ng/ml, which increased in intensity up to the highest concentration of doxycycline used (Figure 3C). These results show a clear correlation between XBP1s expression and the repression of IRE1α-mediated cleavage of endogenous XBP1.

The expression of exogenous XBP1s should lead to the up-regulation of a number of proteins that are known to alleviate ER stress. Hence, the expression of XBP1s could prevent or suppress the tunicamycin-mediated activation of IRE1α, thereby repressing its RNase activity. To determine the consequence of XBP1s expression on ER expansion, we stained cells with ER Tracker, a dye that binds to potassium channels prominent at the ER membrane. Green fluorescence per cell was seen to increase following doxycycline treatment in CHO-S XB but not CHO-S cells, as quantified by FACS analysis (Figure 4A). This result indicates that the expression of exogenous XBP1 does indeed cause an expansion in the ER, as seen previously when XBP1s is overexpressed in CHO cells. To determine whether XBP1s expression leads to a suppression of other branches of the UPR, we...
evaluated the activation of PERK, indicated by autophosphorylation. PERK phosphorylation was assayed by a shift in electrophoretic mobility to a slower migrating form after UPR induction, exemplified after treatment with DTT or with an inhibitor of PERK kinase activity (PERKi). There was no effect on PERK phosphorylation after treatment with a variety of UPR inducers (DTT, thapsigargin or tunicamycin) in the presence or absence of doxycycline in CHO-S XB cells. This result indicates that there is still a robust UPR activated following treatment with tunicamycin in cells overexpressing XBP1s as judged by PERK phosphorylation.

To further evaluate the relative effect of exogenous XBP1s expression on Ire1α or PERK function we monitored their activation over a range of tunicamycin concentrations (Figure 5). To allow more accurate quantification of endogenous XBP1 splicing we separated the PCR products by PAGE gels allowing a clear separation of the spliced and unspliced forms (Figure 5A). Following quantification we observed that endogenous XBP1 splicing was efficient in the absence of exogenous XBP1s expression reaching a maxima at concentrations above 5μg/ml tunicamycin. Splicing was dramatically repressed at all concentrations of tunicamycin when tested in the presence of exogenous XBP1s (Figure 5C). Interestingly, while the response to the inducer was repressed the sensitivity was similar with splicing occurring at 1μg/ml tunicamycin in the absence or presence of exogenous XBP1s. PERK was almost completely activated at the lower concentrations of tunicamycin (1μg/ml) in the presence or absence of XBP1s expression with no differences either in the sensitivity or level of the response (Figure 5B, D). This result demonstrates that the differential effect of UPR induction on IRE1/Parkin activation is not due to differences in their sensitivity to the inducer, rather it suggests that overexpression of XBP1s suppresses the Ire1α response while not affecting PERK.
Discussion

Activation of the IRE1α branch of the UPR can lead to a variety of outcomes based on regulation of its RNase activity. This activity is tightly controlled by a number of mechanisms, including the transcript and protein levels of IRE1α, changes to its quaternary structure and by its phosphorylation and redox state. Our results indicate an additional mechanism of IRE1α feedback regulation involving XBP1s, which is able to repress RNase activity towards XBP1u. This regulation was revealed upon overexpression of XBP1s and occurred in the absence and presence of ER stress.

Overexpression of XBP1s leads to high levels of expression of XBP1s protein, to the expansion of the ER and an increased expression of secreted proteins. Preconditioning the ER to stress by XBP1s expression could prevent IRE1α activation, thereby repressing splicing of endogenous XBP1u. However, we showed that robust activation of PERK still occurs in cells overexpressing XBP1s upon ER stress. In addition the effect of exogenous XBP1s expression was to suppress IRE1α activity rather than alter its sensitivity towards UPR induction. As the mechanism for PERK and IRE1α activation requires BiP dissociation it seems unlikely that the suppression of Ire1α is due to increased levels of BiP. Hence, activation of IRE1α should occur even in the presence of XBP1s. The repression of IRE1α ability to splice XBP1u is, therefore, most likely to occur downstream of its activation during stress conditions.

Activation of IRE1α leads to its phosphorylation, which has been shown to promote dimerisation of its cytosolic domain. This suggests that phosphorylation activates IRE1α, whereas a phosphatase could be responsible for attenuating IRE1α. One phosphatase, PP2Ce, has been suggested to perform this role; however, the promoter for this gene does not display the ERSE, ERSE-II or UPRE consensus sequences characteristic of genes

Figure 5. Differential effect of PERK and Ire1 activation is not due to differences in sensitivity to UPR induction. (A) Expression of spliced exogenous XBP1 in CHO XB cells was induced by incubation with 1µg/ml doxycycline for 48 hours (refreshed after 24 hours). The cells were incubated with a tunicamycin (TM) concentration range as indicated for three hours. The samples were analysed for unspliced (XBP1u) and spliced (XBP1s) by RT-PCR, with actin as loading control (markers indicated as base pairs on the right). (B) In a separate experiment, induced and uninduced CHO XB cells were treated with the same tunicamycin concentration range as in (A) for three hours and analysed by SDS-PAGE and Western blot with an anti-PERK and anti-actin antibody (molecular weight markers indicated in kDa on the right). (C and D) Quantification of spliced CHO XBP1 and phospho-PERK of (A) and (B), respectively. The results in (C) and (D) are from a single experiment. The experiments in (A) and (B) were carried out three times with consistent results.
upregulated by XBP1α. Also, it has been shown that hyperphosphorylation rather than dephosphorylation of yeast IRE1 is required to deactivate this protein. Nevertheless, the possibility remains that an XBP1s-inducible phosphatase could attenuate the activity of IRE1α during prolonged induction of the UPR.

Alternatively, XBP1α could block the initial phosphorylation and dimerisation of IRE1α in order to reduce the overall intensity of IRE1α signalling. In support of this hypothesis, it was reported that XBP1α works in complex with Sec63 and BiP to negatively regulate IRE1α autophosphorylation. A mouse Sec63 knockout cell line was shown to constitutively activate IRE1α phosphorylation, regardless of the presence of ER stress. Intriguingly, this study revealed that the overexpression of XBP1α in the Sec63 knockout cell line was able to abolish the activation of IRE1α almost entirely, even in the presence of tunicamycin, indicating that Sec63 and XBP1α work in concert to regulate IRE1α phosphorylation. However, this study did not examine the effect of XBP1α overexpression on IRE1α activation in a cell line with physiological levels of Sec63; circumstances that would be closer to the conditions used in the results reported here.

The abundance of IRE1α can be modulated by proteasomal degradation initiated by ubiquitination by the E3 ubiquitin ligase synoviolin (SYVN1), otherwise known as the ERAD component HRD1. The ubiquitination of BiP-bound IRE1α monomers by SYVN1 leads to its dislocation from the ER and degradation by the proteasome. Under normal physiological conditions, BiP-bound IRE1α is continually degraded by ERAD, but the detachment of BiP allows for IRE1α to bypass interaction with SYVN1 and undergo accumulation and activation. Like other components of ERAD, SYVN1 is upregulated by XBP1s so it can be assumed that CHO-S XB would display high levels of SYVN1. This could lead to a reduction in IRE1α protein in XBP1s overexpressing cells; however, as only BiP-bound IRE1α is targeted for ERAD it is only this inactive form that would be affected by XBP1s upregulation and not activated dimers. However, there is precedent for a reduction in total IRE1α unrelated to proteasomal degradation in the presence of stress. Heat shock treatment was shown to deplete IRE1α in a range of mammalian cell lines in a manner that could not be blocked by a proteasome inhibitor. The UPR was activated in these cells, indicated by the presence of IRE1α phosphorylation and other UPR hallmarks, but the specific mechanism for the degradation of IRE1α could not be clarified, and was attributed to an unknown method of suppressing extreme UPR signalling. It is possible that this mechanism could be mediated via XBP1s.

While we have noted here that XBP1s overexpression repressed XBP1u splicing, we have not investigated whether there is any suppression or even activation of activity towards other RNA substrates. It has been shown previously that overexpression of XBP1s had no effect on cell viability under non-stress conditions. Hence, under these conditions there was no suppression or activation of IRE1α RNase activity towards substrates other than XBP1u. It remains to be determined whether under stress conditions and in the presence of excess XBP1s, repression of IRE1α RNase activity extends to all mRNAs not just XBP1u.

Dysregulated IRE1α is a known contributing factor to a number of diseases, including multiple myeloma, epithelial cancers, Parkinson’s disease and inflammatory bowel disease. Hence, increased knowledge of the regulatory mechanisms controlling IRE1α activity will help in understanding the pathogenesis of these diseases, as well as improving any therapeutic intervention.

Data availability
The uncropped western blots, agarose and PAGE gels, and the FACS files can be found on the Open Source Framework (DOI: 10.17605/OSF.IO/BGCDF;26)

Competing interests
No competing interests were disclosed.

Grant information
The work was supported by the Wellcome Trust [103720]; and Biotechnology and Biological Sciences Research Council [BB/K004395/1].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
We thank Marie Anne Pringle for support during this work.

References


Open Peer Review

Current Peer Review Status: ✔ ✔

Version 2

Reviewer Report 17 October 2017
https://doi.org/10.21956/wellcomeopenres.13868.r26825

© 2017 Benham A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adam M. Benham
Department of Biosciences, Durham University, Durham, UK

The authors have included new data (Figure 5 of the revised manuscript) and controls to strengthen the work and have provided an acceptable rebuttal to the points raised in review.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 09 October 2017
https://doi.org/10.21956/wellcomeopenres.13868.r26824

© 2017 Marciniak S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stefan J. Marciniak
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK

The authors have now performed the main experiment suggested in my review. This shows that expression of exogenous XBP1s suppresses the splicing of endogenous XBP1 mRNA without having a detectable effect on the activation of PERK. This answers my concern and so I am satisfied to recommend acceptance.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
This is an interesting report suggesting that novel feedback mechanisms exist to control ER stress responses in mammalian cells. The finding that exogenous XBP1 can repress the splicing of endogenous XBP1 without repressing PERK is noteworthy and suggests ways that in future, manipulation of individual branches of the UPR pathway could be used to target protein misfolding in disease, or to harness the ER more efficiently for the production of recombinant proteins. The paper is clearly written and the interpretation of the results is sound, although there are some aspects of the work that should be followed up.

In Figure 1 (lane 4), there appear to be weak protein bands induced at 75 kD and 100 kD that react with the XBP1 antisera. Since these bands do not appear in the non-induced lysates, they may be specific. It would be interesting, therefore, to determine XBP1 expression and antibody reactivity in CHO-S XB cells induced with doxycycline and then treated +/- ER stress.

The authors state that “as the mechanism for PERK and Ire1 activation requires BiP dissociation it seems unlikely that the absence of Ire1activation is due to increased levels of BiP.” This assertion could be directly tested by examining what happens to BiP mRNA and protein levels in the overexpressing cells versus control cells (+/- ER stress).

In Figure 4, the experiments have been performed only once and the results, whilst clear, cannot be analysed statistically and are therefore somewhat preliminary. I would like to see the experiments in Figure 4 repeated, including a loading/blotting control for Figure 4C.

In Figure 4A, the flow cytometry data suggesting that ER expansion has occurred in the CHOS-XB cells is indirect, as the intracellular distribution of the dye may be influenced by stress responses. Taking this work forward in the future, it will be important to quantitate ER expansion directly e.g. in an adherent cell line, where ER shape and size can be assessed by confocal or electron microscopy.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?  
Yes

If applicable, is the statistical analysis and its interpretation appropriate?  
Partly

Are all the source data underlying the results available to ensure full reproducibility?  
Yes

Are the conclusions drawn adequately supported by the results?  
Yes

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Author Response 27 Jun 2017**

**Neil Bulleid,** University of Glasgow, Glasgow, UK

We thank the referee for insightful comments. We are currently carrying out further experimentation to address the concerns.

**Competing Interests:** No competing interests were disclosed.

---

**Author Response 28 Sep 2017**

**Neil Bulleid,** University of Glasgow, Glasgow, UK

We thank the reviewer for his comments. We have now submitted a revised version of the paper and address the reviewer’s comments below.

1. The weak protein bands seen in figure 1 that have a slower modility than XBP1 are indeed only present in the induced sample and are identified with the antibody as containing XBP1. It has been show previously that XBP1 can be modified by SUMOylation so we presume that these additional protein bands are due to this modification. We include a sentence in the results to suggest this possibility.

2. The differential effect of exogenously expressed XBP1 has now been tested by determining the effect of a range of tunicamycin concentrations on XBP1 splicing or PERK activation. This additional experiment indicates that Ire1 is activated and as sensitive to UPR inducers in the presence of exogenous XBP1 as in its absence, but its splicing activity is dramatically repressed. This results does not address the consequence of BiP dissociation from Ire1 or PERK directly but it clarifies that there is a supression of activity rather than activation.

3. We have now carried out a repeat of Figure 4C with a loading control. (see ORF (DOI: 10.17605/OSF.io/BGCDE;)}
4. We note the suggestion by the reviewer.

**Competing Interests:** No competing interests were disclosed.

---

**Reviewer Report 06 June 2017**

[Link to reviewer report]

---

© 2017 Marciniak S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

---

**Stefan J. Marciniak**

Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK

Protein misfolding in the endoplasmic reticulum (ER), ER stress, activates an unfolded protein response (UPR). This UPR defends the cell by attenuating protein synthesis, enhancing ER chaperone levels and activity, and increasing ER-associated protein degradation. Three signalling pathways make up the UPR, each initiated by a separate ER stress sensor, IRE1α, PERK, and ATF6. These differ in their downstream signalling and in their kinetics of activation and deactivation. Activated IRE1α initiates the splicing of the mRNA encoding XBP1. Unspliced XBP1 mRNA encodes an inactive protein, XBP1u, while spliced XBP1 mRNA encodes an active transcription factor, XBP1s. XBP1s activates genes that increase ER chaperone expression and cause expansion of the ER.

In the study of Chalmers et al, cells were generated that express active XBP1s protein in response to treatment with doxycycline. This caused expansion of the ER, consistent with induction of the known gene expression programme of XBP1s. When forced to express exogenous XBP1s, these cells also showed reduced splicing of endogenous XBP1u when treated with tunicamycin, an inhibitor of glycosylation commonly used to induce ER stress. In contrast, activation of PERK in response to ER stress-inducing agents (DTT, tunicamycin, or thapsigargin) appeared to remain unaffected.

This is a well-written paper. The proposed direct feedback mechanism linking XBP1s to inhibition of XBP1u splicing would be an important finding if it could be demonstrated definitively; however, the current version of the paper leaves a second (less interesting) mechanism still to be excluded.

**Main concern**

The authors suggest that XBP1s selectively blocks splicing of endogenous XBP1u, and that this does not involve a simple generalised resistance of the ER to stress. The authors acknowledge the second possibility in their discussion, but dismiss it because (i) PERK activation persists following induction of XBP1s and (ii) PERK and IRE1α are known to share a similar mechanism of activation. However, differences in the sensitivity of IRE1α and PERK to ER stress could account for their observations. If PERK were to be more sensitive than IRE1α to ER stress, then induction of BiP (or any process downstream of XBP1s that ameliorates ER stress) could block activation of IRE1α while leaving PERK apparently unaffected. This would occur if the concentration of stressor used were to be above the threshold required to activate PERK but below that required to activate IRE1α. To address this, ranges of DTT, tunicamycin, and thapsigargin concentrations could be tested for their effects on IRE1α and PERK.
in the presence and absence of overexpressed XBP1s. If a selective negative feedback mechanism exists linking XBP1s to the inhibition of XBP1u splicing, then the EC50s of these agents will increase only for the activation of IRE1α.

**Minor concerns**

1. It is unclear why the phosphorylation of IRE1α has not been measured. This would help determine at what stage XBP1s antagonizes IRE1α signaling.

2. The kinetics of activation and deactivation of IRE1α and PERK differ significantly\(^3\). Have these been examined in this system?

3. Does expression of XBP1s inhibit the activity of an IRE1α cytosolic domain activated independently of ER stress, e.g. the IRE1 constructs described in refs\(^3,8\)?

**References**


**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Author Response 28 Sep 2017**

**Neil Bulleid**, University of Glasgow, Glasgow, UK

The main concern of this reviewer was that the results could be explained if the sensitivity of Ire1 or PERK to UPR induction was different so that, at the concentrations we are using, there could be a differential effect. We carried out the experiment suggested by the reviewer, i.e. a titration of the response to tunicamycin in the absence or presence of exogenous XBP1. We include the result as a new figure in our revised version (Figure 5). Interestingly the result demonstrates that the exogenous XBP1 suppresses Ire1 splicing activity but does not alter its sensitivity towards the inducer. The conclusion is that Ire1 can still be activated but its activity is in some way inhibited by the presence of exogenous XBP1. No effect was seen for PERK which showed the same sensitivity to the UPR inducer in the presence or absence of exogenous XBP1.

The minor concerns of the reviewer can be addressed as follows:

1. We have tried several commercial antibodies to IRE1α but none recognise the hamster protein. We can indirectly conclude that Ire1α is activated from the splicing assays carried out but cannot assay its phosphorylation status.

2. We have not carried out an analysis of the kinetics of activation or inactivation. As our comparison is between the absence of presence of exogenous XBP1, we focused on the difference between the splicing activity towards endogenous XBP1 in this paper.

3. We have not carried out the experiments with the cytosolic domains of Ire1α suggested by the reviewer. We do know that in the absence of an exogenous agent to activate the UPR we still see a suppression of XBP1 splicing in the presence of exogenous XBP1. This is likely due to a low level of ER stress that occurs even in the absence of external agents.

**Competing Interests:** No competing interests were disclosed.